低剂量阿米替林滴定治疗肠易激综合征作为二线治疗(ATLANTIS试验):基层医疗随机双盲安慰剂对照试验方案
ATLANTIS是一项在英格兰三个地区基层医疗开展的随机、多中心、平行组、两臂、双盲、安慰剂对照试验,计划纳入518例一线治疗仍有症状的成人肠易激综合征患者,按1:1随机接受低剂量阿米替林或安慰剂治疗6个月。阿米替林起始10 mg每晚,根据副作用和治疗反应滴定至最大30 mg每晚。主要目的是确定阿米替林对比安慰剂在6个月时改善患者报告的肠易激综合征整体症状的有效性。
要点
- ATLANTIS试验评估低剂量阿米替林作为基层医疗肠易激综合征二线治疗。
- 518例成人患者按1:1随机接受阿米替林或安慰剂治疗6个月。
- 阿米替林起始10 mg每晚,滴定至最大30 mg每晚。
核心结论
- 确定低剂量阿米替林作为基层医疗肠易激综合征二线治疗的临床和成本效果,将为管理决策提供可靠证据。
研究设计与样本
- 随机、多中心、平行组、两臂、双盲、安慰剂对照试验,在英格兰西约克郡、韦塞克斯和英格兰西部三个地区的全科诊所招募。
- 计划纳入518例一线治疗仍有症状的成人肠易激综合征患者,按1:1随机接受阿米替林或相同安慰剂治疗6个月。
- 阿米替林起始10 mg(或一片安慰剂)每晚,根据副作用和治疗反应滴定至最大30 mg每晚。
- 在基线及随机化后3、6、12个月进行患者报告的评估。
关键数值与推荐
- 主要目的是确定阿米替林对比安慰剂在6个月时改善患者报告的肠易激综合征整体症状的有效性(使用肠易激综合征严重程度评分系统)。
- 次要结局包括肠易激综合征症状缓解、对肠易激综合征相关躯体症状的影响(患者健康问卷-12)、焦虑和抑郁(医院焦虑抑郁量表)、工作和参与其他活动的能力(工作和社会适应量表)、治疗的可接受性和耐受性、自我报告的医疗保健使用、健康相关生活质量(EQ-5D-3L)和成本效果。
- 嵌套定性研究将探讨患者和全科医生对治疗和试验参与的经历,包括可接受性、依从性、非预期效应以及阿米替林在基层医疗肠易激综合征中更广泛使用的意义。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Irritable bowel syndrome (IBS) is a common functional bowel disorder that has a considerable impact on patient quality of life and substantial societal and health care resource costs. Current treatments are often ineffective. Tricyclic antidepressants have shown promise in secondary care populations but their effectiveness in a primary care setting remains unclear. METHODS: ATLANTIS is a randomised, multi-centre, parallel-group, two-arm, double-blind, placebo-controlled trial of low-dose amitriptyline as a second-line treatment for IBS in primary care. Participants will be invited by letter, or recruited opportunistically, from general practices in three regions of England (West Yorkshire, Wessex, and West of England) and screened for eligibility. A total of 518 adult patients with IBS, who are symptomatic despite first-line therapies, will be randomised 1:1 to amitriptyline or identical placebo for 6 months. Treatment will commence at a dose of 10 mg (or one placebo tablet) daily at night, with dose titration up to a maximum of 30 mg at night, depending on side effects and response to treatment. Participant-reported assessments will be conducted at baseline and 3, 6, and 12 months post-randomisation. The primary objective is to determine the effectiveness of amitriptyline, compared with placebo, in improving participant-reported global symptoms of IBS at 6 months (using the IBS Severity Scoring System). Secondary outcomes include relief of IBS symptoms, effect on IBS-associated somatic symptoms (Patient Health Questionnaire-12), anxiety and depression (Hospital Anxiety and Depression Scale), ability to work and participate in other activities (Work and Social Adjustment Scale), acceptability and tolerability of treatment, self-reported health care use, health-related quality of life (EQ-5D-3L), and cost-effectiveness. A nested, qualitative study will explore patient and general practitioner experiences of treatments and trial participation, including acceptability, adherence, unanticipated effects, and implications for wider use of amitriptyline for IBS in primary care. DISCUSSION: Determining the clinical and cost-effectiveness of low-dose amitriptyline as a second-line treatment for IBS in primary care will provide robust evidence to inform management decisions. TRIAL REGISTRATION: ISRCTN ISRCTN48075063 . Registered on 7th June 2019.
引用
- Alderson SL, Wright-Hughes A, Ford AC, et al. Amitriptyline at low-dose and titrated for irritable bowel syndrome as second-line treatment (The ATLANTIS trial): protocol for a randomised double-blind placebo-controlled trial in primary care. Trials. 2022. PMID: 35804433. doi:10.1186/s13063-022-06492-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。